These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 21540399)
21. AIDS-defining neoplasm prevalence in a cohort of HIV-infected patients, before and after highly active antiretroviral therapy. Mayor AM; Gómez MA; Ríos-Olivares E; Hunter-Mellado RF Ethn Dis; 2008; 18(2 Suppl 2):S2-189-94. PubMed ID: 18646347 [TBL] [Abstract][Full Text] [Related]
22. Toxoplasmosis in HIV/AIDS: a living legacy. Nissapatorn V Southeast Asian J Trop Med Public Health; 2009 Nov; 40(6):1158-78. PubMed ID: 20578449 [TBL] [Abstract][Full Text] [Related]
23. Hyponatremia, acute kidney injury, and mortality in HIV-related toxoplasmic encephalitis. Libório AB; Silva GB; Silva CG; Lima Filho FJ; Studart Neto A; Okoba W; de Bruin VM; Araújo SM; Daher EF Braz J Infect Dis; 2012; 16(6):558-63. PubMed ID: 23146154 [TBL] [Abstract][Full Text] [Related]
25. Changes in acquired immunodeficiency syndrome-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy: incidence, presentation, treatment, and survival. Diamond C; Taylor TH; Aboumrad T; Anton-Culver H Cancer; 2006 Jan; 106(1):128-35. PubMed ID: 16329140 [TBL] [Abstract][Full Text] [Related]
27. Toxoplasmic encephalitis and primary lymphoma of the brain--the shift in epidemiology: a case series and review of the literature. Olatinwo TF; Herbowy MT; Hewitt RG AIDS Read; 2001 Sep; 11(9):444-9. PubMed ID: 11682917 [TBL] [Abstract][Full Text] [Related]
28. Prophylaxis and treatment of opportunistic infection in patients on HAART. Tantisiriwat W; Powderly WG AIDS Read; 1999; 9(2):122-30. PubMed ID: 12728894 [TBL] [Abstract][Full Text] [Related]
29. Pyrimethamine for primary prophylaxis of toxoplasmic encephalitis in patients with human immunodeficiency virus infection: a double-blind, randomized trial. ANRS 005-ACTG 154 Group Members. Agence Nationale de Recherche sur le SIDA. AIDS Clinical Trial Group. Leport C; Chêne G; Morlat P; Luft BJ; Rousseau F; Pueyo S; Hafner R; Miro J; Aubertin J; Salamon R; Vildé JL J Infect Dis; 1996 Jan; 173(1):91-7. PubMed ID: 8537688 [TBL] [Abstract][Full Text] [Related]
30. Toxoplasmic encephalitis IRIS in HIV-infected patients: a case series and review of the literature. Martin-Blondel G; Alvarez M; Delobel P; Uro-Coste E; Cuzin L; Cuvinciuc V; Fillaux J; Massip P; Marchou B J Neurol Neurosurg Psychiatry; 2011 Jun; 82(6):691-3. PubMed ID: 20660912 [TBL] [Abstract][Full Text] [Related]
31. Assessing the impact of HAART on the incidence of defining and non-defining AIDS cancers among patients with HIV/AIDS: a systematic review. Cobucci RN; Lima PH; de Souza PC; Costa VV; Cornetta Mda C; Fernandes JV; Gonçalves AK J Infect Public Health; 2015; 8(1):1-10. PubMed ID: 25294086 [TBL] [Abstract][Full Text] [Related]
32. Risk factors for Kaposi's sarcoma in human immunodeficiency virus patients after initiation of antiretroviral therapy: A nested case-control study in Kenya. Lupia R; Wabuyia PB; Otiato P; Fang CT; Tsai FJ J Microbiol Immunol Infect; 2017 Dec; 50(6):781-788. PubMed ID: 26712092 [TBL] [Abstract][Full Text] [Related]
33. Lack of change in the distribution of AIDS-defining opportunistic diseases and the related degree of immunodeficiency during the periods before and after the introduction of highly active antiretroviral therapy. Manfredi R; Calza L; Chiodo F Eur J Clin Microbiol Infect Dis; 2001 Jun; 20(6):410-3. PubMed ID: 11476442 [TBL] [Abstract][Full Text] [Related]
34. AIDS events among individuals initiating HAART: do some patients experience a greater benefit from HAART than others? Sabine C; AIDS; 2005 Nov; 19(17):1995-2000. PubMed ID: 16260906 [TBL] [Abstract][Full Text] [Related]
35. [A retrospective cohort study on reduction of AIDS mortality among patients enrolled in national-free antiretroviral treatment programme in two cities in China]. Dou ZH; Zhao Y; He Y; He WS; Ji GP; Xu C; Ma Y; Zhao DC; Yu L; Zhang FJ Zhonghua Yu Fang Yi Xue Za Zhi; 2009 Dec; 43(12):1091-5. PubMed ID: 20193506 [TBL] [Abstract][Full Text] [Related]
36. Association between Highly Active Antiretroviral Therapy and Type of Infectious Respiratory Disease and All-Cause In-Hospital Mortality in Patients with HIV/AIDS: A Case Series. Báez-Saldaña R; Villafuerte-García A; Cruz-Hervert P; Delgado-Sánchez G; Ferreyra-Reyes L; Ferreira-Guerrero E; Mongua-Rodríguez N; Montero-Campos R; Melchor-Romero A; García-García L PLoS One; 2015; 10(9):e0138115. PubMed ID: 26379281 [TBL] [Abstract][Full Text] [Related]
37. [Primary prophylaxis of cerebral toxoplasmosis in AIDS with clarithromycin]. Esvant H; Legoupil I; Gaillat J; Bru JP Presse Med; 1993 May; 22(18):877. PubMed ID: 8337221 [No Abstract] [Full Text] [Related]
38. AIDS-related focal brain lesions in the era of highly active antiretroviral therapy. Ammassari A; Cingolani A; Pezzotti P; De Luca DA; Murri R; Giancola ML; Larocca LM; Antinori A Neurology; 2000 Oct; 55(8):1194-200. PubMed ID: 11071499 [TBL] [Abstract][Full Text] [Related]
39. Risk of toxoplasmic encephalitis in AIDS patients: indications for prophylaxis. Dunlop O; Rootwelt V; Sannes M; Goplen AK; Abdelnoor M; Skaug K; Baklien K; Skar A; Melby K; Myrvang B; Bruun JN Scand J Infect Dis; 1996; 28(1):71-3. PubMed ID: 9122637 [TBL] [Abstract][Full Text] [Related]
40. A study for precision diagnosing and treatment strategies in difficult-to-treat AIDS cases and HIV-infected patients with highly fatal or highly disabling opportunistic infections: Study protocol for antiretroviral therapy timing in AIDS patients with toxoplasma encephalitis. Zeng YM; Li Y; He XQ; Huang YQ; Liu M; Yuan J; Bai Y; Lu YQ; Li H; Chen YK Medicine (Baltimore); 2020 Jul; 99(29):e21141. PubMed ID: 32702867 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]